14-day Premium Trial Subscription Sign Up For FreeGet Free

$0.70 (-0.84%)

Volume: 1M

Closed: Dec 08, 2021

Hollow Logo Score: 0.373

Agile Therapeutics Stock Forecast

$0.70 (-0.84%)

Volume: 1M

Closed: Dec 08, 2021

Score Hollow Logo 0.373
Which way will AGRX go? Request
Stop-loss: $0.67 (-3.96%)
Key Stats
Beta 1.05
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] RSI14 is 52 and the stock is currently not being overbought or oversold

Big movements in Agile Therapeutics stock price on Wednesday moving 13.83% between high and low
(Updated on Dec 08, 2021)


Buy or Hold candidate since 2021-12-07 Loss -0.84%

The Agile Therapeutics stock price fell by -0.84% on the last day (Wednesday, 8th Dec 2021) from $0.71 to $0.70. During the day the stock fluctuated 13.83% from a day low at $0.65 to a day high of $0.74. The price has risen in 6 of the last 10 days and is up by 21.8% over the past 2 weeks. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -2 million shares and in total, 1 million shares were bought and sold for approximately $866.95 thousand.

The stock lies the upper part of a very wide and falling trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break up at the top trend line at $0.74 will firstly indicate a slower falling rate, but may be the first sign of a trend shift. Given the current short-term trend, the stock is expected to fall -41.08% during the next 3 months and, with a 90% probability hold a price between $0.29 and $0.43 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Signals & Forecast

A buy signal was issued from a pivot bottom point on Friday, November 26, 2021, and so far it has risen 27.11%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The Agile Therapeutics stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term moving average at $0.72. On a fall, the stock will find some support from the short-term average at $0.64. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. Volume fell along with the price during the last trading day, which is technical positive. One should, however, note that this stock may have low liquidity in periods, which increases the general risk.

Support, Risk & Stop-loss

Agile Therapeutics finds support from accumulated volume at $0.67 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move much during the day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.0899 between high and low, or 13.83%. For the last week the stock has had a daily average volatility of 13.00%.

Our recommended stop-loss: $0.67 (-3.96%) (This stock has high daily movements and this gives high risk. There is a buy signal from a pivot bottom found 8 days ago.)

Is Agile Therapeutics stock A Buy?

Agile Therapeutics holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Buy to a Hold/Accumulate candidate.

Current score: 0.373

Predicted Opening Price for Agile Therapeutics of Thursday, December 9, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price December 9, 2021 Current price
$0.70 $0.70 (Overvalued)
Hold/Accumulate Downgraded

Remember To Visit Our YouTube Channel

Analyst Ratings

On Nov 03, 2021 "HC Wainwright" gave "$3.50 - $2.50" rating for AGRX. The price target was changed from $0.80 to 6.6%.

Volatility and Risk
Daily Average Volatility: 13.00 %
Overall Risk: Very High High Medium Low Very Low
Volatility
13.00 %
Daily Average Volatility
Overall Risk

Very High
High
Medium
Low
Very Low

Support & Resistance

Resistance: $0.71
Price: $0.70
Support: $0.67

AGRX Insider Trading Show all Trades

Date Action Amount Person Type
Show all Insider Trades
INSIDER POWER

Last 0 transactions
Buy: 0 | Sell: 0 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 0.79 12.36 %
0.75 7.46 %
0.73 4.42 %
Current price: 0.70
Support 0.66 -5.39 %
0.64 -8.42 %
0.61 -13.32 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 0.86 22.86 %
0.77 9.91 %
0.71 0.71 %
Current price 0.70
Support 0.67 -3.63%
0.64 -9.06%
0.63 -10.00%

Click to get the best stock tips daily for free!

About Agile Therapeutics

Agile Therapeutics Agile Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, a once-weekly contraceptive patch, which is in Phase III clinical development. The company is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cyc... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT